PT  - JOURNAL ARTICLE
AU  - NAOHIRO NISHIDA
AU  - MAKOTO YAMSAKI
AU  - KAZUKI ODAGIRI
AU  - KOTARO YAMASHITA
AU  - KOJI TANAKA
AU  - DAISUKE SAKAI
AU  - TOMOKI MAKINO
AU  - TSUYOSHI TAKAHASHI
AU  - YUKINORI KUROKAWA
AU  - TAROH SATOH
AU  - MASAKI MORI
AU  - YUICHIRO DOKI
TI  - Combination Therapy With S-1, Oxaliplatin and Leucovorin in Patients With Advanced Esophageal Squamous Cell Carcinoma
AID  - 10.21873/invivo.11730
DP  - 2019 Nov 01
TA  - In Vivo
PG  - 2249--2254
VI  - 33
IP  - 6
4099  - http://iv.iiarjournals.org/content/33/6/2249.short
4100  - http://iv.iiarjournals.org/content/33/6/2249.full
SO  - In Vivo2019 Nov 01; 33
AB  - Background/Aim: In this study, we assessed the safety and efficacy of combination therapy with S-1, oxaliplatin and leucovorin (SOL) in advanced esophageal squamous cell carcinoma (ESCC) patients. Patients and Methods: Ten unresectable or recurrence ESCC patients, who had been previously treated with more than two regimens were included in this study. The treatment schedule comprised S-1 40-60 mg and fixed dose of leucovorin 25 mg together orally twice a day for one week, followed by one-week of rest. Oxaliplatin 85 mg/m2 was given as an intravenous infusion on day one, repeated every two weeks. Results: Of the eight patients with measurable lesions, two patients with partial response (25%) and two with stable disease (25%) were observed. Disease control rate was 50%. Median progression-free survival and overall survival were 5.0 and 9.3 months, respectively. The main common adverse events were malaise (60%), decreased appetite (50%), peripheral sensory neuropathy (40%). Conclusion: SOL therapy showed promising antitumor activity with acceptable toxicity even for heavily pretreated ESCC.